, a biopharmaceutical business focused on innovative remedies that address unmet medical requirements in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA’s proprietary product candidate currently in Stage III advancement for Parkinson’s disease psychosis, may have also therapeutic benefits in the treating Alzheimer’s disease psychosis . Results of the scholarly studies were released in the scientific journal, Behavioural Pharmacology . These animals developed psychosis-like behaviors with enhanced responses to the psychostimulants DOI and amphetamine in addition to disrupted prepulse inhibition.Centers for Disease Avoidance and Control. All of those injuries are due to falls Nearly. After surgery, many sufferers need nursing home care, and about 20 % of all hip-fracture sufferers die within a year, according to the CDC. Fracture medical procedures typically involves fixing the injury with screws – – and it’s actually simpler than hip substitute, Devereaux said. However, hip substitute is planned beforehand, stated Dr. Douglas Lundy, a spokesman for the American Academy of Orthopaedic Surgeons, who was simply not mixed up in study.